Company news

MediciNova, Inc. news in 2026

MediciNova, Inc.'s news releases, calls and decks from 2026, newest first.

View company

MediciNova CEO Provides Shareholder Update

October 12, 2026

MediciNova to Participate in the Maxim Growth Summit

October 6, 2026

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

September 29, 2026

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

September 28, 2026

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

September 24, 2026

MediciNova to Participate in Two Investor Conferences in September

September 8, 2026

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

July 15, 2026

MediciNova CEO Provides Shareholder Update

June 30, 2026

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

June 8, 2026

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

May 26, 2026

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

April 27, 2026

MediciNova to Participate at the 38th Annual ROTH Conference

March 16, 2026

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

January 29, 2026

2026 New Year’s Greetings from the CEO

January 6, 2026

Decks in 2026